QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Denali Therapeutics Inc. (DNLI)

Healthcare

Actionable
Fundamental
3
Sentiment
4
Technical
3

Buy limit 19.65 (GTC) on the 19.63-19.65 support shelf holding above the rising SMA20/EMA21 after the 17.37 to 22.19 rally, with MACD back above zero. Protective stop 18.74 (1.0xATR pullback floor; structural 19.45), targets 21.47 / 22.84, R/R 2.00; all gates passed (price 19.73 <= 25, F3/Q4, max overnight gap 1.72% <= 5%, recent 3-session dollar volume ~$15.7M >= $1.5M, no events in the holding window through 2026-12-03).

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

Denali Therapeutics Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing treatments for neurodegenerative diseases. Its pipeline includes candidates for Parkinson's disease, Hunter syndrome, ALS, and cutaneous lupus erythematosus, with several in various stages of clinical trials. The company collaborates with multiple partners, including Takeda and Genentech.

Fundamental

fair
Fundamental3
Early commercialization

Denali is transitioning to early commercialization with strong liquidity but remains loss-making and dependent on pipeline success.

Denali has entered the early commercial phase with FDA accelerated approval of AVLAYAH and initial product sales, but it is still deeply loss-making with sizable ongoing cash burn. Liquidity is strong (about $940M in cash and marketable securities at 6/30/26 plus a ~$195M priority-review-voucher sale in July 2026), yet near-term upside depends on launch execution and pipeline/confirmatory outcomes rather than current earnings power.

Sentiment

good
Sentiment4
Improving sentiment

Media sentiment has improved following early AVLAYAH launch revenue, despite past setbacks in the Parkinson's program.

Recent coverage has turned modestly positive on Q2 results that highlighted early AVLAYAH launch-revenue traction (announced), improving the media tone versus the prior 30–90d window that was weighed down by the BIIB122 Parkinson’s setback. Red-Flag Screen clean (no regulator-confirmed investigations or material litigation surfaced).

Technical

fair
Technical3
Pullback-to-support

The stock is consolidating above key moving averages, suggesting a potential rebound from support levels.

Pullback-to-support setup inside a recovering uptrend: DNLI rallied +28% from the 17.37 mid-October low to 22.19 on 2026-11-04 and has spent five sessions consolidating in a 19.63-20.69 range on declining volume (873K shares today vs 4.9M on the 11-04 distribution day), holding above a rising SMA20 (19.15) and EMA21 (19.55). MACD has reclaimed zero (line 0.05 vs signal -0.14, histogram +0.19, third positive session), and the 19.65 / 19.625 lows of 11-05 / 11-11 define a clear support shelf just 0.4% below the last price. Mixed signals keep this a score-3 chart rather than a 4: price is still below SMA50 (19.93), SMA200 (21.25) and the 19.87 daily VWAP, RSI14 50.92 is neutral, and the MACD histogram is contracting (0.28 to 0.24 to 0.19). Structure still supports a limit bid at support with a 1.0xATR-floored stop and 2.0 R/R.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.